Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | DRD4 | P21917 | 6/20 | 0.44 |
| ▸ | DRD3 | P35462 | 5/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446839 | 0.89 | SMN1; SMN2 (0.58) | ALDH1A1SMN1; SMN2L3MBTL1TSHRPKM | |
| SCHEMBL5457605 | 0.88 | SMN1; SMN2 (0.57) | ALDH1A1SMN1; SMN2L3MBTL1TSHRPKM | |
| SCHEMBL5454690 | 0.88 | SMN1; SMN2 (0.57) | ALDH1A1SMN1; SMN2L3MBTL1TSHRPKM | |
| SCHEMBL14411398 | 0.85 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2L3MBTL1TSHRPKM | |
| SCHEMBL5455205 | 0.83 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2L3MBTL1TSHRPKM | |
| SCHEMBL5451167 | 0.78 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2L3MBTL1TSHRPKM | |
| SCHEMBL5449584 | 0.78 | CNR2 (0.53) | ALDH1A1SMN1; SMN2L3MBTL1TSHRDRD2 | |
| SCHEMBL5444542 | 0.76 | CNR2 (0.60) | ALDH1A1SMN1; SMN2L3MBTL1TSHRDRD2 | |
| SCHEMBL5463442 | 0.76 | MAPT (0.57) | ALDH1A1SMN1; SMN2L3MBTL1TSHRDRD2 | |
| SCHEMBL5447266 | 0.75 | MEN1 (0.50) | ALDH1A1SMN1; SMN2L3MBTL1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007079239-A2 | BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | ALDH1A1 2963/4885SMN1; SMN2 1701/4885L3MBTL1 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.